Monoclonal antibody against α4 integrins for the treatment of multiple sclerosis and inflammatory bowel disease.
Indicated for the treatment of relapsing forms of MS.
Antibody against α4 integrins which inhibit the binding of cells such as lymphocytes, which express integrins, to vascular cell adhesion molecules on endothelial cells, a step necessary for diapedesis of lymphocytes across blood vessels into the CNS or mucosal organs.
Treatment prevents inflammatory cells from crossing the blood brain barrier and inhibits the accumulation of immune cells in the CNS.
A humanized IgG4 antibody that is a member of an adhesion molecule inhibitors.
α4 integrins selectively involve leukocyte transport to the gut and brain.
Inhibits both Alpha4beta1and Alpha4beta7 integrins and hass been associated with progressive multifocal leukoencephalopathy.
Blocks lymphocyte trafficking in multiple organs, including the brain and gut.
May be associated with progressive multifocal leukoencephalopathy (PML).
Of approximatley 20,000 patients with multiple sclerosis have been treated with this agent for 18 months or more and about 1 case per 1000 patients develop PML.
Risk factors for PML include duration of natalizumab therapy, presence of the JC virus, and prior immunosuppressive therapy.
Risk factors for PML include duration of natalizumab therapy, presence of the JC virus, and prior immunosuppressive therapy.
The more infusions a patient receives the greater the risk of developing progressive multifocal leukoencephalopathy.
Forces hematopoietic stem cells and pre-B cells to migrate from the bone marrow since they cannot bind to vascular cell adhesion molecules due to the inhibition of alpha-integrin binding.
One of the risks of natalizumab is the occurrence of progressive multifocal leukoencephalopathy (PML), which can result in morbidity and mortality.
Risk factors for PML include duration of natalizumab therapy, presence of the JC virus, and prior immunosuppressive therapy.